Skip to main content

People in the News: Jun 24, 2010


Oligonucleotide manufacturer Girindus has named Edward Huber as its director of analytical development and quality control.

Huber previously held a variety of positions at Marion Merrell Dow, Hoechst Marion Roussel, Aventis, and Patheon. He has a PhD in analytical chemistry from the University of Cincinnati.

Agios Pharmaceuticals has appointed Alnylam Pharmaceuticals CEO John Maraganore to its board of directors.

Maraganore is the first independent director of Agios, which is developing drugs in the area of cancer metabolism.

Prior to Alnylam, Maraganore was an officer and a member of the management team for Millennium Pharmaceuticals, where he was oversaw the company's efforts in oncology, cardiovascular, inflammation, and metabolic diseases. Before Millennium, he worked in molecular biology and business development at Biogen, ZymoGenetics, and the Upjohn Company.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.